181 related articles for article (PubMed ID: 9696505)
1. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.
Zoulim F; Trépo C
J Hepatol; 1998 Jul; 29(1):151-68. PubMed ID: 9696505
[No Abstract] [Full Text] [Related]
2. [Efficacy and problems in combination therapy using lamivudine and interferon for chronic hepatitis B].
Saito T; Watanabe H; Togashi H; Kawata S
Nihon Rinsho; 2004 Aug; 62 Suppl 8():326-30. PubMed ID: 15453339
[No Abstract] [Full Text] [Related]
3. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
[TBL] [Abstract][Full Text] [Related]
4. How to overcome antiviral-resistant hepatitis B virus?
Song BC
Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.
Aberle SW; Kletzmayr J; Watschinger B; Schmied B; Vetter N; Puchhammer-Stöckl E
J Clin Microbiol; 2001 May; 39(5):1972-4. PubMed ID: 11326026
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B.
Hussain M; Lok AS
J Viral Hepat; 1999 May; 6(3):183-94. PubMed ID: 10607230
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naïve patients with chronic hepatitis B.
Nguyen MH; Garcia RT; Trinh HN; Nguyen HA; Nguyen KK; Nguyen LH; Levitt B
Aliment Pharmacol Ther; 2009 Dec; 30(11-12):1150-8. PubMed ID: 19785624
[TBL] [Abstract][Full Text] [Related]
8. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.
Ogata N; Fujii K; Takigawa S; Nomoto M; Ichida T; Asakura H
J Med Virol; 1999 Nov; 59(3):270-6. PubMed ID: 10502255
[TBL] [Abstract][Full Text] [Related]
9. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Bourlière M
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
[No Abstract] [Full Text] [Related]
10. [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Marcellin P; Lada O
Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S5-8. PubMed ID: 17075487
[No Abstract] [Full Text] [Related]
11. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
[TBL] [Abstract][Full Text] [Related]
12. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
14. Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients.
Ji D; Liu Y; Si LL; Li L; Chen GF; Xin SJ; Zhao JM; Xu D
Clin Chim Acta; 2011 Jan; 412(3-4):305-13. PubMed ID: 21056552
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?
Zoulim F
Antivir Chem Chemother; 2004 Nov; 15(6):299-305. PubMed ID: 15646643
[TBL] [Abstract][Full Text] [Related]
16. [Entecavir therapy against hepatitis B].
Kato N; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():340-4. PubMed ID: 15453342
[No Abstract] [Full Text] [Related]
17. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
18. Management of hepatitis B patients with antiviral resistance.
Fung SK; Lok AS
Antivir Ther; 2004 Dec; 9(6):1013-26. PubMed ID: 15651760
[TBL] [Abstract][Full Text] [Related]
19. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
Zhang Q; Chen J; Pan M; Liu J; Liu T; Zhou YH
Virus Res; 2018 Aug; 255():165-170. PubMed ID: 30075160
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis B: focus on telbivudine.
Lui YY; Chan HL
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):259-68. PubMed ID: 19344240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
